A medical expert answers your common questions about memory loss, causes of dementia, diagnosis, prevention, treatment, and more. Perhaps someone in your family has been diagnosed with Alzheimer disease—or maybe you worry about developing memory loss yourself. In Is It Alzheimer's?, Dr. Peter V. Rabins, a top expert in the field, educates readers by answering 101 often-asked questions about memory loss and dementia. Written in a conversational, easy-to-use Q&A style, the book is organized into seven unique sections. A companion to the best-selling The 36-Hour Day, which Dr. Rabins coauthored, this book discusses • how to distinguish typical memory loss from early dementia • how dementia is diagnosed • what factors play a role in the progression of dementia • whether it's possible to lower your risk of developing Alzheimer disease or dementia • how to improve the quality of life of people with dementia • how to assess long-term care facilities and nursing homes • available treatments, including medication • how to explain the symptoms of Alzheimer disease and dementia to others • how to provide caregivers with psychological and emotional support • and much more Aimed at friends and family members of the estimated 5.1 million US adults with dementia, as well as adults who are concerned about developing dementia, the book offers helpful directions and comfort. Is It Alzheimer's? is a quick, accessible, and essential reference for anyone who hopes to navigate the confusion of dementing illnesses.

A definitive and compelling book on one of today's most prevalent illnesses. In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2050. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center.

A reference on preventing, treating, and coping with dementia, from “one of the most reliable, respected health resources that Americans have” (Publishers Weekly). This book from the world-renowned Mayo Clinic offers an update on what experts know about Alzheimer’s and related dementias, including the latest research into treatment and prevention, ways to live well with dementia, and recommendations for caregivers. While Alzheimer’s disease is the most common type of dementia, many related types also affect adults worldwide, causing loss of memory, reason, judgment, and other cognitive functions. Although the diseases that cause dementia have long been considered unrelenting and incurable, recent advances offer hope. This book includes information about: • What to expect of typical aging and what are the earliest signs of abnormal aging • Memory loss and other forms of cognitive impairment that may lead to dementia • Characteristic features of Alzheimer’s disease and related dementias, including frontotemporal degeneration, Lewy body dementia, and vascular cognitive impairment • The latest research on Alzheimer’s disease and related dementias • Caring for and supporting someone living with dementia Are there ways you can lower your risk? Can dementia be prevented? Can you live well with dementia? If so, how? You’ll find answers to these important questions and more in this book.

New edition, completely rewritten, with new chapters on endovascular surgery and mitochrondrial and ion channel disorders.

Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies - Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease - Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease - Provides a comparison of the effectiveness of various types of treatments

Alzheimer’s disease, a haunting and harrowing ailment, is one of the world’s most common causes of death. Alzheimer’s lingers for years, with patients’ outward appearance unaffected while their cognitive functions fade away. Patients lose the ability to work and live independently, to remember and recognize. There is still no proven way to treat Alzheimer’s because its causes remain unknown. Mind Thief is a comprehensive and engaging history of Alzheimer’s that demystifies efforts to understand the disease. Beginning with the discovery of “presenile dementia” in the early twentieth century, Han Yu examines over a century of research and controversy. She presents the leading hypotheses for what causes Alzheimer’s; discusses each hypothesis’s tangled origins, merits, and gaps; and details their successes and failures. Yu synthesizes a vast amount of medical literature, historical studies, and media interviews, telling the gripping stories of researchers’ struggles while situating science in its historical, social, and cultural contexts. Her chronicling of the trajectory of Alzheimer’s research deftly balances rich scientific detail with attention to the wider implications. In narrating the attempts to find a treatment, Yu also offers a critical account of research and drug development and a consideration of the philosophy of aging. Wide-ranging and accessible, Mind Thief is an important book for all readers interested in the challenge of Alzheimer’s.

Although the public most often associates dementia with Alzheimer’s disease, the medical profession continues to advance distinctions of various types of “other” dementias. What If It’s Not Alzheimer’s? is the first and remains the only comprehensive guide dealing with frontotemporal degeneration (FTD), the most common form of dementia for people under 60 years of age. The contributors are either specialists in their fields or have exceptional hands-on experience with FTD sufferers. Beginning with a focus on the medical facts, the first part defines and explores FTD as an illness distinct from Alzheimer's disease. Also considered are clinical and medical care issues and practices, as well as such topics as finding a medical team, palliative approaches to managing care and rehabilitation interventions. The next section on managing care examines the daily care routine including exercise, socialization, adapting the home environment, and behavioral issues along with end-of-life concerns. In the following section on caregiver resources, the contributors identify professional and government assistance programs along with private and community resources and legal options. The final section focuses on the caregiver, in particular the need for respite, holistic health practices and the challenge of managing emotions. This new, completely revised edition continues to follow worldwide collaboration in research and provides the most current medical information available including understanding of the different classifications of FTD, and more clarity regarding the role of genetics. Additionally, essays written by people living with the disease provide moving, first-hand experiences. The wealth of information offered in these pages will help both healthcare professionals and caregivers of someone suffering from frontotemporal degeneration.

A guide to dealing with a diagnosis of Alezheimer's: coping with the diagnosis, managing symptoms, plannig for the future, keeping hope and humor, participating in research, and more.

The instant New York Times and Wall Street Journal bestseller A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline. Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline. Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene. The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.

The book aims to present, educate and inform individuals about Alzheimer's disease in a comprehensive manner. Its scope ranges from the discovery of the disease, epidemiology and basic biological principles underlying it, to advanced stem cell therapies used in the treatment of Alzheimer's. It adopts a 'global' perspective on Alzheimer's disease, and include epidemiological data and science from countries around the world.Alzheimer's disease is a rapidly growing problem seen in every country around the world. This is the first and only comprehensive book to cover Alzheimer's disease, and includes the most updated literature and scientific progress in the field of dementia and Alzheimer's disease research.Most books on the market that focus on Alzheimer's disease are targeted at caregivers as practical advice on how to deal with loved ones with the disease. This book instead is a comprehensive and popular science book that can be read by anyone with an interest in learning more about the disease.Dr. Jefferson Chen MD, PhD, co-author, participated in the world's first surgical clinical trial using shunts to treat Alzheimer's disease. His first-hand involvement in a clinical trial for patients with Alzheimer's disease and experience treating Normal Pressure Hydrocephalus (NPH) which is commonly misdiagnosed as Alzheimer's disease lends a unique perspective.This book with appeal to a wide audience, regardless of their scientific or educational background.